Full-Time

Data Manager

Updated on 5/8/2026

Matterworks

Matterworks

11-50 employees

AI-powered MaaS for metabolomics data

No salary listed

Cambridge, MA, USA

Hybrid

Hybrid model; in-office presence at Somerville, MA may be required for hands-on work.

Category
Biology & Biotech (1)
Required Skills
Python
SQL
Machine Learning
Data Governance
Requirements
  • 6+ years of demonstrated experience owning scientific data work end-to-end (curation, standardization, QC, documentation, governance) in bioinformatics, cheminformatics, computational biology, scientific data engineering, or related roles.
  • Ability to navigate complex chemical and biological datasets, reconcile identifiers/metadata across sources, and make data consistently usable for end users.
  • Strong attention to detail with a keen ability to balance priorities and delivery incremental value while operating with minimal oversight.
  • Comfortable building structure from scratch: you can define processes, set standards, and iterate toward scalable practices in an early-stage environment.
  • Practical proficiency in Python and SQL for data investigation, transformation, QC, and automation.
  • Familiarity with modern data workflows (structured + semi-structured data, pipelines, reproducibility, documentation).
  • Experience with chemical structure representations and normalization (e.g., SMILES/InChI, canonicalization, salt/tautomer handling, stereochemistry considerations).
  • Demonstrated ability to communicate and collaborate with product, machine learning, applied science and engineers while reducing complex business questions into valuable, reliable technical solutions.
  • A passion for contributing to an early-stage startup where autonomy, eagerness to learn, and enthusiasm for solving novel scientific challenges prevail over rigid processes and egos.
Responsibilities
  • Data Strategy & E2E Ownership: Partner with scientific, ML, and product stakeholders to define a data roadmap: which datasets move the needle, which should be refreshed, and what “good enough” looks like for each use case. Establish clear success metrics for onboarding speed, dataset quality, and downstream usability (e.g., fewer training/data failures, higher match rates, better coverage, higher-confidence labels).
  • Dataset Sourcing, Discovery, and Intake: Proactively scout and integrate public and client datasets, plus relevant literature and reference materials, to keep our corpora current and comprehensive. Design a repeatable dataset intake workflow including provenance, source tracking, and refresh cadence.
  • Data Curation, Quality and Governance: Define curation standards that make data consistent across sources and modalities, including compound identity management, biological/sample metadata standardization, and schema + conventions mappings. Build a scalable approach to integrating metabolomics now and expanding to additional omics without reinventing everything each time. Develop practical QC/QA frameworks that combine scientific judgment with repeatable checks.
  • Cross-Functional Collaboration: Work closely with leadership in engineering, AI, product, and scientific discovery to align initiatives with company-wide goals. Use experience to keep initiatives moving smoothly. Translate ambiguous questions into crisp data requirements, priorities, and execution plans. Build trust across disciplines by being both scientifically rigorous and pragmatically execution oriented.

Matterworks applies artificial intelligence to metabolomics to make mass spectrometry data easier to analyze. It offers a model-as-a-service platform that lets researchers identify and quantify metabolites from raw data, using its Large Spectral Model (LSM) to interpret molecular-omic information. Its Pyxis product provides turn-key, near real-time metabolite profiling, reducing analysis time and enabling faster decision-making in therapeutic research, biomanufacturing, crop science, and animal health. By delivering end-to-end AI for omics data, Matterworks aims to lower costs and broaden access to advanced metabolomics, helping life sciences R&D move from data to actionable insight more quickly.

Company Size

11-50

Company Stage

Seed

Total Funding

$13.8M

Headquarters

Somerville, Massachusetts

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Series A in June 2025 from Lewis & Clark and OMX funds MaaS expansion.
  • Pyxis beta with top pharma validates applications in biomarkers and cell-line development.
  • New CFO Paul Stone and CSO Jennifer Campbell accelerate partnerships.

What critics are saying

  • Metabolon captures market share with broader assays in 12-24 months.
  • Recursion poaches ML experts from 25-person team in 12-18 months.
  • $15.9M runway ends in 18-24 months amid 2026 biotech downturn.

What makes Matterworks unique

  • Matterworks' Pyxis uses Large Spectral Models for untargeted metabolomics annotation.
  • Pyxis reduces LC-MS analysis from weeks to five minutes per sample.
  • MaaS model delivers AI-driven metabolite insights across biomanufacturing and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Matterworks who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Long-term Disability Insurance

Short-term Disability Insurance

Life Insurance

401(k) Retirement Plan

Stock Options

Flexible Work Hours

Unlimited Paid Time Off

Remote Work Options

Paid Vacation

Paid Holidays

Commuter Benefits

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

2%

2 year growth

4%
PR Newswire
Feb 17th, 2026
Matterworks appoints Paul Stone as CFO to expand life sciences AI platform partnerships

Matterworks, a frontier AI company providing predictive biology tools for life sciences, has appointed Paul Stone as Chief Financial Officer and Head of Corporate Development. Stone brings 28 years of experience in venture capital and operating roles, most recently as partner at 5AM Ventures and previously as CFO at IDEAYA Biosciences. The Somerville, Massachusetts-based company's platform uses Large Spectral Models for machine interpretation of biochemical data to predict complex biological outcomes. Matterworks has demonstrated applications across target identification, compound optimisation, biomarker discovery, patient stratification, cell-line development and bioprocess development. CEO Jack Geremia said the appointment supports expansion of commercial and partnership development activities as the company engages with pharmaceutical and biotech firms to enhance efficiency in research, development and manufacturing.

WN.com
Jun 3rd, 2025
Matterworks Secures Series A Funding

Matterworks, Inc., based in Somerville, Mass., announced securing Series A funding to advance machine intelligence for predictive biology. The financing round was led by Lewis & Clark Partners and OMX Ventures, with participation from Pillar VC, Germin8 Ventures, and Intermountain Ventures.

PR Newswire
Jun 3rd, 2025
MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

/PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, today announces new Series A...

PR Newswire
May 2nd, 2024
Matterworks Announces Updates To Leadership Team

SOMERVILLE, Mass., May 2, 2024 /PRNewswire/ -- Matterworks, Inc., whose foundational AI platform and predictive biology applications accelerate life sciences discovery and development, today announces additions to its leadership team.Matterworks is pleased to announce the appointments of Jennifer M. Campbell, Ph.D. to the position of Chief Scientific Officer and Niall O'Connor to the position of Chief Technology Officer.Dr. Campbell is a distinguished leader in mass spectrometry and molecular analysis, bringing 25 years of expertise to the role. She joined Matterworks from Novartis Institutes of Biomedical Research in 2021 to lead R&D from initial product conceptualization through development and early customer testing. In late 2023 Dr

AgFunderNews
Apr 4th, 2024
🎥 Germin8 Ventures On A ‘Bruising’ Year In Venture Capital, And New Opportunities In ‘Frontier Science And Computation’

In 2023, agrifoodtech represented just 5.5% of all venture capital sector dollars, down from 6.7% in 2022 and 7.6% in 2021, despite the fact that the food ag industry accounts for almost a fifth of global GDP and is a major contributor to climate change. And with funding continuing to decline, is it time to panic?. At the recent World Agri-Tech innovation summit in San Francisco, we caught up with Michael Lavin, managing partner at Germin8 Ventures, a long-time investor in the sector to discuss:Where are we in the current down cycle?. What is getting funded now and why? What is Germin8 excited about?